This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The patient whose ECG is shown in Figure-1 — presented with acute dyspnea and hypotension. QUESTION: In Figure-1 — Is the rhythm VT? — How certain are you of your answer? Figure-1: The initial ECG in today's case. ( To improve visualization — I've digitized the original ECG using PMcardio ). == MY Thoughts on the ECG in Figure-1: Although at first glance, the ECG in Figure-1 appears to be wide — this is a false initial impression!
The 24-month data showed a notable response rate in study eyes treated with a high dose of AGTC-501, with a generally safe and tolerable clinical profile.
Publication date: Available online 18 October 2024 Source: The American Journal of Cardiology Author(s): Evan Czulada, Jamal D. Smith, Paul Kolm, Brototo Deb, Sarahfaye F. Dolman, Nebu Alexander, Ryan A. Braun, Rajiv A. Kabadi, William S.
A new meta-analysis found elevated triglyceride levels in patients with major depressive disorder, potentially explaining the link between depression and cardiovascular risks.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Given the distrust some patients with conditions such as alopecia areata and psoriasis have regarding JAK inhibitors, this analysis highlights several approaches to such concerns.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
111 
Let's personalize your content